SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 1316-1321. Prepublished online as a Blood First Edition Paper on October 3, 2006; DOI 10.1182/blood-2006-08-039909. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-08-039909v1 109/3/1316    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kröger, N. Articles by Fehse, B. Search for Related Content PubMed PubMed Citation Articles by Kröger, N. Articles by Fehse, B. Related Collections Neoplasia Transplantation Oncogenes and Tumor Suppressors Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis Nicolaus Kröger1, Anita Badbaran1, Ernst Holler2, Joachim Hahn2, Guido Kobbe3, Martin Bornhäuser4, Andreas Reiter5, Tatjana Zabelina1, Axel R. Zander1, and Boris Fehse1 1 Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Germany; 2 Department of Hematology/Oncology, University Hospital Regensburg, Germany; 3 Department of Hematology/Oncology, University Hospital Düsseldorf, Germany; 4 Department of Hematology/Oncology, University Hospital Dresden, Germany; 5 Department of Hematology/Oncology, University Hospital Mannheim, Germany The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and might be a reliable marker to monitor residual disease after allogeneic stem cell transplantation. We describe a new, highly sensitive ( 0.01%) real-time polymerase chain reaction (PCR) to monitor and quantify V617F-JAK2–positive cells after dose-reduced allogeneic stem cell transplantation. After 22 allogeneic stem cell transplantation procedures in 21 JAK2-positive patients with myelofibrosis, 78% became PCR negative. In 15 of 17 patients (88%), JAK2 remained negative after a median follow-up of 20 months. JAK2 negativity was achieved after a median of 89 days after allograft (range, 19-750 days). A significant inverse correlation was seen for JAK2 positivity and donor-cell chimerism (r: –0.91, P < .001). Four of 5 patients who never achieved JAK2 negativity fulfilled during the entire follow-up all criteria for complete remission recently proposed by the International Working Group, suggesting a major role for JAK2 measurement to determine depths of remission. In one case, residual JAK2-positive cells were successfully eliminated by donor lymphocyte infusion. In conclusion, allogeneic stem cell transplantation after dose-reduced conditioning induces high rates of molecular remission in JAK2-positive patients with myelofibrosis, and quantification of V617F-JAK2 mutation by real-time PCR allows the detection of minimal residual disease to guide adoptive immunotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Cankovic, L. Whiteley, R. C. Hawley, R. J. Zarbo, and D. Chitale Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods Am J Clin Pathol, November 1, 2009; 132(5): 713 - 721. [Abstract] [Full Text] [PDF] J. B. Perz, U. Hegenbart, N. Kroeger, G. Otto, A. D. Ho, and P. Dreger Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation Haematologica, April 1, 2009; 94(4): 594 - 596. [Full Text] [PDF] N. Kroger, H. Alchalby, E. Klyuchnikov, A. Badbaran, Y. Hildebrandt, F. Ayuk, U. Bacher, O. Bock, M. Kvasnicka, B. Fehse, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation Blood, February 19, 2009; 113(8): 1866 - 1868. [Full Text] [PDF] E. Lippert, F. Girodon, E. Hammond, J. Jelinek, N. S. Reading, B. Fehse, K. Hanlon, M. Hermans, C. Richard, S. Swierczek, et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study Haematologica, January 1, 2009; 94(1): 38 - 45. [Abstract] [Full Text] [PDF] A. Theocharides, J. R. Passweg, M. Medinger, R. Looser, S. Li, H. Hao-Shen, A. S. Buser, A. Gratwohl, A. Tichelli, and R. C. Skoda The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders Haematologica, December 1, 2008; 93(12): 1890 - 1893. [Abstract] [Full Text] [PDF] D. Rondelli Allogeneic hematopoietic stem cell transplantation for myelofibrosis Haematologica, October 1, 2008; 93(10): 1449 - 1450. [Full Text] [PDF] F. Patriarca, A. Bacigalupo, A. Sperotto, M. Isola, F. Soldano, B. Bruno, M. T. van Lint, A. P. Iori, S. Santarone, F. Porretto, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Haematologica, October 1, 2008; 93(10): 1514 - 1522. [Abstract] [Full Text] [PDF] A. Pancrazzi, P. Guglielmelli, V. Ponziani, G. Bergamaschi, A. Bosi, G. Barosi, and A. M. Vannucchi A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction J. Mol. Diagn., September 1, 2008; 10(5): 435 - 441. [Abstract] [Full Text] [PDF] A. Rambaldi, T. Barbui, and G. Barosi From Palliation to Epigenetic Therapy in Myelofibrosis Hematology, January 1, 2008; 2008(1): 83 - 91. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020